Background: Sigma Healthcare is the company behind pharmacy brands like Amcal and Guardian, alongside a major wholesale and distribution arm. Last year, Sigma merged with Chemist Warehouse in an $8.8 billion backdoor listing, creating a $34.5 billion ASX-listed pharma powerhouse.

What happened: In its first half results, roughly a year on from the merger, earnings jumped 18.7% to nearly $582 million. On top of this, revenue rose 14.9% to $5.5 billion, while international sales climbed 24.5% to $807 million.

What else: The Sigma management acknowledged that profitability overseas isn’t the immediate focus, but investors were clearly satisfied. For now, the domestic business is doing the heavy lifting, meaning the international expansion can take place without pressure for instant returns.

What's the key learning?

💡Investors are often willing to be patient with overseas expansion… but only if the core business is humming. In Sigma’s case, Australian sales are strong, same-store sales are growing and earnings are rising — which makes the market more relaxed about offshore profits not being the priority.

💡Right now, the international division makes up around 13% of turnover. If it scales successfully, that’s upside. If it takes time, the core domestic engine is still delivering solid results.

💡Contrast that with Guzman y Gomez. When it expanded into the US, America was positioned as central to its growth story. With that pressure, its shares have fallen more than 45% over the past 12 months. The market is far more forgiving when global growth is optional rather than essential.